The event is sponsored by Amgen. Amanda Hernandez, MD, PhD of University of Connecticut, Amit Sachdev, MD or Michigan State University and Gil Wolfe, MD, FAAN of the University of Buffalo, will discuss the MINT study of UPLIZNA, followed by an overview of UPLIZNA as the first and only FDA-approved CD19-targeted therapy for adults with generalized myasthenia gravis (gMG) who have anti-AChR or anti-MuSK antibodies. Using clear, real-world patient examples, the program will highlight how a twice-yearly infusion schedule may help reduce symptoms, lessen treatment burden, and support daily functioning for patients living with myasthenia gravis. This is a live national video broadcast event that will be shown at the restaurant.